Introduction Publications Technical Details Ordering MSDS

IntegriSense 680: targeting integrin αvβ3
IntegriSense 680 can reveal new, important information about the important role played by integrin αvβ3 in angiogenesis, tumor cell metastasis and the action of potential anti-angiogenic therapeutics that are targeted towards integrins.
IntegriSense 680
Absorbance and emission spectra in 1 x PBS
MW
1432 g/mol
Fluorescence Excitation1
675 nm
Fluorescence Emission1
693 nm
Absorbance
675 nm ± 5 nm
Purity2
>95%
Appearance
Dark blue solid, soluble in water or aqueous buffer
Storage Conditions
Protect from light. Store at 4°C
1. Absorbance and fluorescence maxima of IntegriSense 680 in 1X PBS
2. As determined by RP-HPLC, measuring absorbance at 675 nm

OsteoSense 680, OsteoSense 750: targeting hydroxyapatite
OsteoSense agents enable in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastases. Results correlate well with traditional clinical measurements of disease
Image bone growth and resorption without the use of radioisotopes
Detect microcalcification and measure osteogenic (bone remodeling) activity
Achieve high sensitivity and resolution - targets hydroxyapatite, a biomarker for osteoblast activity
Perform serial or multiplex imaging - OsteoSense 680 and
OsteoSense 750
Use in conventional reflectance or tomographic imaging systems
Enlarge
Schematic of OsteoSense: biphosphonate fluorescence agents target hydroxyapatite
About hydroxyapatite
Development and maintenance of the skeleton depends upon a balance between osteoblast and osteoclast activity. Changes in this balance are characteristic of numerous skeletal disease states.
Hydroxyapatite (HA) is the major mineral product of osteoblasts and a biomarker for osteoblast activity. OsteoSense 750 and OsteoSense 680 target hydroxyapatite (exposed during times of bone turnover), binding with high affinity, to enable in vivo detection and monitoring of skeletal changes that occur during either bone growth or bone resorption.
OsteoSense 680
Absorbance and emission spectra in 1 x PBS
MW ~1075 g mol-1
Fluorescence Excitation 680 ± 10 nm
Fluorescence Emission 700 ± 10 nm
Absorbance 680 ± 10 nm
Purity (determined by SE-HPLC, measuring absorbance at 680 nm) >95%
Appearance Clear blue solution
OsteoSense 750
Absorbance and emission spectra in 1 x PBS
MW ~1100 g mol-1
Fluorescence Excitation 750 ± 10 nm
Fluorescence Emission 780 ± 10 nm
Absorbance 750 ±10 nm
Purity (determined by SE-HPLC, measuring absorbance at 750 nm) >95%
Appearance Clear blue solution
Fluorescence Agent Preparation
The products below are supplied lyophilized or in concentrated form for dilution in 1 x PBS (not supplied) prior to injection.
Product Supplied concentration Recommended injection concentration Recommended injection volume for an ~25 gram mouse
OsteoSense 680 20 nmol/150 μl in 1 x PBS 2 nmol /150μl in 1 x PBS 150 μL
OsteoSense 750 20 nmol/150 μl in 1 x PBS 2 nmol /150μl in 1 x PBS 150 μL
IntegriSense 680 24 nmol lyophilized 2 nmol/100 μl in 1 x PBS 100 μL
Administration of Fluorescence Agents
Allow fluorescence agents to reach room temperature before injection.
Inject agents intravenously via the tail vein.
Use a small gauge (27G) needle and dispense slowly into the tail vein.
Imaging Time Points
Fluorescence agent Recommend imaging time
post tail vein injection.
OsteoSense 680 24 hours
OsteoSense 750 24 hours
IntegriSense 680 0.5 – 24 hrs post injection
For additional information and application support, please contact us